Senate health committee chair demands Novo, Sanofi drop insulin costs after Lilly
Sen. Bernie Sanders (I-VT) has long been critical of Big Pharma, and in light of Eli Lilly’s price cuts on its insulins yesterday, which Sanders praised, he’s calling on Novo Nordisk and Sanofi to do the same.
The identical letters from March 1 addressed to Novo Nordisk CEO Lars Fruergaard Jørgensen and Sanofi CEO Paul Hudson insisted that the two companies join Eli Lilly in lowering the price of insulin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.